Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

William G. Wierda, John C. Byrd, Susan O'Brien, Steven Coutre, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Jan A. Burger, Don A. Stevens, Jeff Sharman, Paolo Ghia, Ian W. Flinn, Cathy Zhou, Joi Ninomoto, Danelle F. James, Constantine S. Tam

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)184-188
Number of pages5
JournalBritish Journal of Haematology
Volume186
Issue number1
DOIs
Publication statusPublished - Jul 2019

Keywords

  • chronic lymphocytic leukaemia
  • genomic risk factors
  • ibrutinib
  • tumour debulking
  • tumour lysis syndrome risk

ASJC Scopus subject areas

  • Hematology

Cite this

Wierda, W. G., Byrd, J. C., O'Brien, S., Coutre, S., Barr, P. M., Furman, R. R., Kipps, T. J., Burger, J. A., Stevens, D. A., Sharman, J., Ghia, P., Flinn, I. W., Zhou, C., Ninomoto, J., James, D. F., & Tam, C. S. (2019). Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 186(1), 184-188. https://doi.org/10.1111/bjh.15791